A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 1, 2008, Pages 99-107

  Dees, E Claire ^a,b   O'Neil, Bert H ^a,b   Lindley, Celeste M ^a   Collichio, Frances ^a,b   Carey, Lisa A ^a,b   Collins, Jason ^a   Riordan, William J ^c   Ivanova, Anastasia ^a   Esseltine, Dixie ^c   Orlowski, Robert Z ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Bortezomib; Breast cancer; Pegylated liposomal doxorubicin; Phase I; Proteasome inhibition

Indexed keywords

BORTEZOMIB; DOXORUBICIN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING DISORDER; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPOXIA; INSOMNIA; LIVER FUNCTION TEST; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FATIGUE; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; LIPOSOMES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS; POLYETHYLENE GLYCOLS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 53149115608     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0716-8     Document Type: Article

References (32)

1. J Adams VJ Palombella EA Sausville J Johnson A Destree DD Lazarus 1999 Proteasome inhibitors: a novel class of potent and effective antitumor agents Cancer Res 59 11 2615 2622
2. PG Richardson P Sonneveld MW Schuster D Irwin EA Stadtmauer T Facon 2005 Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 24 2487 2498
3. PG Richardson B Barlogie J Berenson S Singhal S Jagannath D Irwin 2003 A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 26 2609 2617
4. OA O'Connor J Wright C Moskowitz J Muzzy B MacGregor-Cortelli M Stubblefield 2005 Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma J Clin Oncol 23 4 676 684
5. A Goy A Younes P McLaughlin B Pro JE Romaguera F Hagemeister 2005 Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma J Clin Oncol 23 4 667 675
6. RI Fisher SH Bernstein BS Kahl B Djulbegovic MJ Robertson S de Vos 2006 Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma J Clin Oncol 24 30 4867 4874
7. CN Papandreou DD Daliani D Nix H Yang T Madden X Wang 2004 Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer J Clin Oncol 22 11 2108 2121
8. MP Fanucchi FV Fossella R Belt R Natale P Fidias DP Carbone 2006 Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer J Clin Oncol 24 31 5025 5033
9. GV Kondagunta B Drucker L Schwartz J Bacik S Marion P Russo 2004 Phase II trial of bortezomib for patients with advanced renal cell carcinoma J Clin Oncol 22 18 3720 3725
10. C Aghajanian S Soignet DS Dizon CS Pien J Adams PJ Elliott 2002 A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies Clin Cancer Res 8 8 2505 2511
11. GK Dy JP Thomas G Wilding L Bruzek S Mandrekar C Erlichman 2005 A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer Clin Cancer Res 11 9 3410 3416
12. PM Voorhees RZ Orlowski 2006 The proteasome and proteasome inhibitors in cancer therapy Annu Rev Pharmacol Toxicol 46 189 213
13. SV Rajkumar PG Richardson T Hideshima KC Anderson 2005 Proteasome inhibition as a novel therapeutic target in human cancer J Clin Oncol 23 3 630 639
14. T Hideshima C Mitsiades M Akiyama T Hayashi D Chauhan P Richardson 2003 Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341 Blood 101 4 1530 1534
15. MR Ranson J Carmichael K O'Byrne S Stewart D Smith A Howell 1997 Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial J Clin Oncol 15 10 3185 3191
16. E Rivera V Valero FJ Esteva L Syrewicz M Cristofanilli Z Rahman 2002 Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer Cancer Chemother Pharmacol 49 4 299 302
17. O Lyass B Uziely R Ben-Yosef D Tzemach NI Heshing M Lotem 2000 Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma Cancer 89 5 1037 1047
18. N Mitsiades CS Mitsiades PG Richardson V Poulaki YT Tai D Chauhan 2003 The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications Blood 101 6 2377 2380
19. GW Small YY Shi NA Edmund S Somasundaram DT Moore RZ Orlowski 2004 Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role Mol Pharmacol 66 6 1478 1490
20. RZ Orlowski PM Voorhees RA Garcia MD Hall FJ Kudrik T Allred 2005 Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies Blood 105 8 3058 3065
21. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 205 216
22. ES Lightcap TA McCormack CS Pien V Chau J Adams PJ Elliott 2000 Proteasome inhibition measurements: clinical application Clin Chem 46 5 673 683
23. A Gabizon R Chisin S Amselem S Druckmann R Cohen D Goren 1991 Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin Br J Cancer 64 6 1125 1132
24. A Gabizon R Catane B Uziely B Kaufman T Safra R Cohen 1994 Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes Cancer Res 54 4 987 992
25. T Caravita P de Fabritiis A Palumbo S Amadori M Boccadoro 2006 Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies Nat Clin Pract Oncol 3 7 374 387
26. PG Richardson H Briemberg S Jagannath PY Wen B Barlogie J Berenson 2006 Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib J Clin Oncol 24 19 3113 3120
27. RZ Orlowski A Nagler P Sonneveld J Blade R Hajek A Spencer 2007 Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression J Clin Oncol 25 25 3892 3901
28. CH Yang AM Gonzalez-Angulo JM Reuben DJ Booser L Pusztai S Krishnamurthy 2006 Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits Ann Oncol 17 5 813 817
29. F Cardoso JS Ross MJ Picart C Sotiriou V Durbecq 2004 Targeting the ubiquitin-proteasome pathway in breast cancer Clin Breast Cancer 5 2 148 157
30. WA Messersmith SD Baker L Lassiter RA Sullivan K Dinh VI Almuete 2006 Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors Clin Cancer Res 12 4 1270 1275
31. C Ma SJ Mandrekar SR Alberts GA Croghan A Jatoi JM Reid 2007 A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies Cancer Chemother Pharmacol 59 2 207 215
32. AA Adjei 2005 Sequencing bortezomib with chemotherapy and targeted agents Clin Lung Cancer 7 Suppl 2 S56 S58